Preoperative imatinib mesylate (IM) for huge gastrointestinal stromal tumors (GIST)
Sumin TangYuan YinChaoyong ShenJiaju ChenXiaonan YinBo ZhangYuqin YaoJinliang YangZhi‐Xin Chen
Abstract
IM prior to surgery can effectively prevent tumor rupture and facilitate surgery with low surgical morbidity for GIST patients. Tumor shrinkage following IM occurred predominantly within 6 to 12 months, and slight tumor shrinkage could be observed after 12 months in certain patients. In selected patients, prolonged exposure to IM is seemingly advisable under close radiological surveillance.
Metrics
Citation History
Topics
Related Documents
Preoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)
Marco FioreElena PalassiniElena FumagalliS. PilottiElena TamboriniSilvia StacchiottiElisabetta PennacchioliPaolo G. CasaliAlessandro Gronchi
Surgical treatment of patients (pts) with gastrointestinal stromal tumors (GIST) after imatinib mesylate (IM) therapy
Piotr RutkowskiZbigniew NoweckiP NyckowskiWirginiusz DziewirskiAnna Nasierowska‐GuttmejerUrszula GrzesiakowskaW. MichejMarcin KrawczykW. Ruka
Preoperative imatinib for locally advanced gastrointestinal stromal tumors (GIST): CONVERT trial.
Bruno dos Santos Vilhena Pereira
Surgery of residual disease following imatinib mesylate in advanced gastrointestinal stromal tumors (GIST)
Alessandro GronchiMarco FioreRossella BertulliMaurizio ColecchiaElena TamboriniS. PilottiA. MessinaPaola CocoSilvia StacchiottiPaolo G. Casali
Immediate action of imatinib mesylate on calcium signaling in gastrointestinal stromal tumors (GIST).
Erik BerglundMin LüPınar AkçakayaJan ZedeniusInga‐Lena NilssonJan ÅhlénWeng‐Onn LuiCatharina LarssonRobert Bränström